Seroatlas · Human Serome Atlas

DNAH17

Dynein axonemal heavy chain 17

Also known as: DNAHL1, DNEL2, DYH17_HUMAN, FLJ40457

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9UFH2
Gene: DNAH17
Ensembl: ENSG00000187775
Chromosome: 17
Canonical length: 4462 aa
Protein class: Disease related genes, Human disease related genes, Predicted intracellular proteins
Subcellular location: Mid piece,Principal piece,End piece

OverviewNCBI Gene

Dyneins are microtubule-associated motor protein complexes composed of several heavy, light, and intermediate chains. DNAH17 is a heavy chain associated with axonemal dynein (Milisav and Affara, 1998 [PubMed 9545504]).[supplied by OMIM, Mar 2008]

Canonical amino-acid sequenceUniProt

4462 residues, UniProt reviewed canonical sequence.

>Q9UFH2|DNAH17
     1  MTMAPDVRLE YLEEVASIVL KFKPDKWSKL IGAEENVALF TEFFEKPDVQ VLVLTLNAAG
    61  MIIPCLGFPQ SLKSKGVYFI KTKSENINKD NYRARLLYGD ISPTPVDQLI AVVEEVLSSL
   121  LNQSENMAGW PQVVSEDIVK QVHRLKNEMF VMSGKIKGKT LLPIPEHLGS LDGTLESMER
   181  IPSSLDNLLL HAIETTIIDW SHQIRDVLSK DSAQALLDGL HPLPQVEFEF WDTRLLNLKC
   241  IHEQLNRPKV NKIVEILEKA KSCYWPALQN VYTNVTEGLK EANDIVLYLK PLRILLEEME
   301  QADFTMLPTF IAKVLDTICF IWATSEYYNT PARIIVILQE FCNQIIEMTR TFLSPEEVLK
   361  GLQGEIEEVL SGISLAVNVL KELYQTYDFC CVNMKLFFKD KEPVPWEFPS SLAFSRINSF
   421  FQRIQTIEEL YKTAIEFLKL EKIELGGVRG NLLGSLVTRI YDEVFELVKV FADCKYDPLD
   481  PGDSNFDRDY ADFEIKIQDL DRRLATIFCQ GFDDCSCIKS SAKLLYMCGG LMERPLILAE
   541  VAPRYSVMLE LFDAELDNAK ILYDAQMAAS EEGNIPLIHK NMPPVAGQLK WSLELQERLE
   601  VSMKHLKHVE HPVMSGAEAK LTYQKYDEMM ELLRCHREKI YQQWVAGVDQ DCHFNLGQPL
   661  ILRDAASNLI HVNFSKALVA VLREVKYLNF QQQKEIPDSA ESLFSENETF RKFVGNLELI
   721  VGWYNEIKTI VKAVEFLLIK SELEAIDVKL LSAETTLFWN GEGVFQYIQE VREILHNLQN
   781  RMQKAKQNIE GISQAMKDWS ANPLFERKDN KKEALLDLDG RIANLNKRYA AVRDAGVKIQ
   841  AMVAENAELF RADTLSLPWK DYVIYIDDMV LDEFDQFIRK SLSFLMDNMV IDESIAPLFE
   901  IRMELDEDGL TFNPTLEVGS DRGFLALIEG LVNDIYNVAR LIPRLAKDRM NYKMDLEDNT
   961  DLIEMREEVS SLVINAMKEA EEYQDSFERY SYLWTDNLQE FMKNFLIYGC AVTAEDLDTW
  1021  TDDTIPKTPP TLAQFQEQID SYEKLYEEVS KCENTKVFHG WLQCDCRPFK QALLSTIRRW
  1081  GFMFKRHLSN HVTNSLADLE AFMKVARMGL TKPLKEGDYD GLVEVMGHLM KVKERQAATD
  1141  NMFEPLKQTI ELLKTYGEEM PEEIHLKLQE LPEHWANTKK LAIQVKLTVA PLQANEVSIL
  1201  RRKCQQFELK QHEFRERFRR EAPFSFSDPN PYKSLNKQQK SISAMEGIME ALSKSGGLFE
  1261  VPVPDYKQLK ACHREVRLLK ELWDMVVVVN TSIEDWKTTK WKDINVEQMD IDCKKFAKDM
  1321  RSLDKEMKTW DAFVGLDNTV KNVITSLRAV SELQNPAIRE RHWQQLMQAT QVKFKMSEET
  1381  TLADLLQLNL HSYEDEVRNI VDKAVKESGM EKVLKALDST WSMMEFQHEP HPRTGTMMLK
  1441  SSEVLVETLE DNQVQLQNLM MSKYLAHFLK EVTSWQQKLS TADSVISIWF EVQRTWSHLE
  1501  SIFIGSEDIR TQLPGDSQRF DDINQEFKAL MEDAVKTPNV VEATSKPGLY NKLEALKKSL
  1561  AICEKALAEY LETKRLAFPR FYFVSSADLL DILSNGNDPV EVSRHLSKLF DSLCKLKFRL
  1621  DASDKPLKVG LGMYSKEDEY MVFDQECDLS GQVEVWLNRV LDRMCSTLRH EIPEAVVTYE
  1681  EKPREQWILD YPAQVALTCT QIWWTTEVGL AFARLEEGYE NAIRDYNKKQ ISQLNVLITL
  1741  LMGNLNAGDR MKIMTICTID VHARDVVAKM IVAKVESSQA FTWQAQLRHR WDEEKRHCFA
  1801  NICDAQIQYS YEYLGNTPRL VITPLTDRCY ITLTQSLHLI MGGAPAGPAG TGKTETTKDL
  1861  GRALGTMVYV FNCSEQMDYK SCGNIYKGLA QTGAWGCFDE FNRISVEVLS VIAVQVKCVQ
  1921  DAIRAKKKAF NFLGEIIGLI PTVGIFITMN PGYAGRAELP ENLKALFRPC AMVVPDFELI
  1981  CEIMLMAEGF LEARLLARKF ITLYTLCKEL LSKQDHYDWG LRAIKSVLVV AGSLKRGDPS
  2041  RAEDQVLMRA LRDFNIPKIV TDDLPVFMGL IGDLFPALDV PRKRDLNFEK IIKQSIVELK
  2101  LQAEDSFVLK VVQLEELLQV RHSVFIVGNA GSGKSQVLKS LNKTYQNLKR KPVAVDLDPK
  2161  AVTCDELFGI INPVTREWKD GLFSTIMRDL ANITHDGPKW IILDGDIDPM WIESLNTVMD
  2221  DNKVLTLASN ERIPLNRTMR LVFEISHLRT ATPATVSRAG ILYINPADLG WNPVVSSWIE
  2281  RRKVQSEKAN LMILFDKYLP TCLDKLRFGF KKITPVPEIT VIQTILYLLE CLLTEKTVPP
  2341  DSPRELYELY FVFTCFWAFG GAMFQDQLVD YRVEFSKWWI NEFKTIKFPS QGTIFDYYID
  2401  PDTKKFLPWT DKVPSFELDP DVPLQASLVH TTETIRIRYF MDLLMEKSWP VMLVGNAGTG
  2461  KSVLMGDKLE SLNTDNYLVQ AVPFNFYTTS AMLQGVLEKP LEKKSGRNYG PPGTKKLVYF
  2521  IDDMNMPEVD KYGTVAPHTL IRQHMDHRHW YDRHKLTLKD IHNCQYVACM NPTSGSFTID
  2581  SRLQRHFCVF AVSFPGQEAL TTIYNTILTQ HLAFRSVSMA IQRISSQLVA AALALHQKIT
  2641  ATFLPTAIKF HYVFNLRDLS NIFQGLLFST AEVLKTPLDL VRLWLHETER VYGDKMVDEK
  2701  DQETLHRVTM ASTKKFFDDL GDELLFAKPN IFCHFAQGIG DPKYVPVTDM APLNKLLVDV
  2761  LDSYNEVNAV MNLVLFEDAV AHICRINRIL ESPRGNALLV GVGGSGKQSL SRLAAYISGL
  2821  DVFQITLKKG YGIPDLKIDL AAQYIKAAVK NVPSVFLMTD SQVAEEQFLV LINDLLASGE
  2881  IPGLFMEDEV ENIISSMRPQ VKSLGMNDTR ETCWKFFIEK VRRQLKVILC FSPVGSVLRV
  2941  RARKFPAVVN CTAIDWFHEW PEDALVSVSA RFLEETEGIP WEVKASISFF MSYVHTTVNE
  3001  MSRVYLATER RYNYTTPKTF LEQIKLYQNL LAKKRTELVA KIERLENGLM KLQSTASQVD
  3061  DLKAKLAIQE AELKQKNESA DQLIQVVGIE AEKVSKEKAI ADQEEVKVEV INKNVTEKQK
  3121  ACETDLAKAE PALLAAQEAL DTLNKNNLTE LKSFGSPPDA VVNVTAAVMI LTAPGGKIPK
  3181  DKSWKAAKIM MGKVDTFLDS LKKFDKEHIP EACLKAFKPY QGNPTFDPEF IRSKSTAAAG
  3241  LCSWCINIVR FYEVYCDVAP KRQALEEANA ELAEAQEKLS RIKNKIAELN ANLSNLTSAF
  3301  EKATAEKIKC QQEADATNRV ILLANRLVGG LASENIRWAE SVENFRSQGV TLCGDVLLIS
  3361  AFVSYVGYFT KKYRNELMEK FWIPYIHNLK VPIPITNGLD PLSLLTDDAD VATWNNQGLP
  3421  SDRMSTENAT ILGNTERWPL IVDAQLQGIK WIKNKYRSEL KAIRLGQKSY LDVIEQAISE
  3481  GDTLLIENIG ETVDPVLDPL LGRNTIKKGK YIKIGDKEVE YHPKFRLILH TKYFNPHYKP
  3541  EMQAQCTLIN FLVTRDGLED QLLAAVVAKE RPDLEQLKAN LTKSQNEFKI VLKELEDSLL
  3601  ARLSAASGNF LGDTALVENL ETTKHTASEI EEKVVEAKIT EVKINEAREN YRPAAERASL
  3661  LYFILNDLNK INPVYQFSLK AFNVVFEKAI QRTTPANEVK QRVINLTDEI TYSVYMYTAR
  3721  GLFERDKLIF LAQVTFQVLS MKKELNPVEL DFLLRFPFKA GVVSPVDFLQ HQGWGGIKAL
  3781  SEMDEFKNLD SDIEGSAKRW KKLVESEAPE KEIFPKEWKN KTALQKLCMV RCLRPDRMTY
  3841  AIKNFVEEKM GSKFVEGRSV EFSKSYEESS PSTSIFFILS PGVDPLKDVE ALGKKLGFTI
  3901  DNGKLHNVSL GQGQEVVAEN ALDVAAEKGH WVILQNIHLV ARWLGTLDKK LEHYSTGSHE
  3961  DYRVFISAEP APSPETHIIP QGILENAIKI TNEPPTGMHA NLHKALDLFT QDTLEMCTKE
  4021  MEFKCMLFAL CYFHAVVAER RKFGAQGWNR SYPFNNGDLT ISINVLYNYL EANPKVPWDD
  4081  LRYLFGEIMY GGHITDDWDR RLCRTYLAEY IRTEMLEGDV LLAPGFQIPP NLDYKGYHEY
  4141  IDENLPPESP YLYGLHPNAE IGFLTVTSEK LFRTVLEMQP KETDSGAGTG VSREEKVKAV
  4201  LDDILEKIPE TFNMAEIMAK AAEKTPYVVV AFQECERMNI LTNEMRRSLK ELNLGLKGEL
  4261  TITTDVEDLS TALFYDTVPD TWVARAYPSM MGLAAWYADL LLRIRELEAW TTDFALPTTV
  4321  WLAGFFNPQS FLTAIMQSMA RKNEWPLDKM CLSVEVTKKN REDMTAPPRE GSYVYGLFME
  4381  GARWDTQTGV IAEARLKELT PAMPVIFIKA IPVDRMETKN IYECPVYKTR IRGPTYVWTF
  4441  NLKTKEKAAK WILAAVALLL QV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against DNAH17 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0
Highest tissue expression: 5.2 nTPM

Expression across tissuesHPA

Tissue

testis: 5.2 nTPM
retina: 2.3 nTPM
skin: 0.3 nTPM
cerebral cortex: 0.2 nTPM
lung: 0.1 nTPM
ovary: 0.1 nTPM

Single-cell type

retinal bipolar cells: 312 nCPM
cone photoreceptor cells: 224 nCPM
neutrophils: 95 nCPM
early spermatids: 70 nCPM
late spermatids: 59 nCPM
late primary spermatocytes: 59 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

white matter: 4.6 nTPM
medulla oblongata: 3.9 nTPM
pons: 3 nTPM
spinal cord: 2.3 nTPM
midbrain: 2.1 nTPM
cerebellum: 1.9 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about DNAH17.

Disease | AllUniProt

Conditions DNAH17 is implicated in, by any mechanism.

Spermatogenic failure 39 (SPGF39) MIM:618643

Disease | GeneticClinVar

23 pathogenic / likely-pathogenic of 1,569 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Spermatogenic failure 39
DNAH17-related disorder
Short stature
Male infertility
Male infertility with spermatogenesis disorder

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.75
gnomAD pLI: 0
gnomAD missense Z: -3.13

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads DNAH17 as an antibody target. Whether an autoantibody or antibody against DNAH17 could matter depends on whether native DNAH17 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

DNAH17 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label DNAH17 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...